Cindy Chmielewski @MyelomaTeacher's Avatar

Cindy Chmielewski @MyelomaTeacher

@myelomateacher

Wife, mother, “retired” educator and animal lover. #Myeloma patient Dx 2008 - Myeloma research advocate #mmsm

238
Followers 78
Following 12
Posts 25.09.2024
Joined
Posts Following

Latest posts by Cindy Chmielewski @MyelomaTeacher @myelomateacher

Post image Post image

First interview of the #EHA25 Day 2. Dr. Litzow of @MayoClinic #mmsm #allsm Remember stop by and share your research. Hearing about your research provides patients with hope. We are located across from Coral 4!

13.06.2025 07:24 👍 1 🔁 0 💬 0 📌 0
Beating T-Cell Exhaustion: The Future of Myeloma Care | Marta Chesi & Erin Meermeier | #ASH24
Beating T-Cell Exhaustion: The Future of Myeloma Care | Marta Chesi & Erin Meermeier | #ASH24 YouTube video by HealthTree Foundation for Multiple Myeloma

Its always nice to hear from the basic researchers. Their successes in the lab eventually transfer to patient care. Thanks! youtu.be/VHE5-RQJnf8?...
#MMsm #ASH24 #HealthTree #myeloma

21.12.2024 18:57 👍 2 🔁 0 💬 0 📌 1
High-Fiber NUTRIVENTION Study for Delaying Progression of Myeloma | Urvi Shah, MD | #ASH24
High-Fiber NUTRIVENTION Study for Delaying Progression of Myeloma | Urvi Shah, MD | #ASH24 YouTube video by HealthTree Foundation for Multiple Myeloma

Can diet change outcomes? youtu.be/ieT73JXu_kc?... #MMsm #ASH24 #myeloma

19.12.2024 17:12 👍 1 🔁 0 💬 0 📌 0
Cevostamab, a FcRH5 bispecific antibody, for RRMM | Joshua Richter, MD | #ASH2024
Cevostamab, a FcRH5 bispecific antibody, for RRMM | Joshua Richter, MD | #ASH2024 YouTube video by HealthTree Foundation for Multiple Myeloma

Today’s ASH highlight video is on Cevostamab-a fixed duration bispecific antibody that targets FCRH5 youtu.be/kHNBPB1S7QY?... #MMsm #ASH24 #HealthTree #myeloma

18.12.2024 17:15 👍 4 🔁 0 💬 0 📌 0
Daratumumab vs Lenalidomide As Myeloma Maintenance Therapy | Sridevi Rajeeve, MD | #ASH24
Daratumumab vs Lenalidomide As Myeloma Maintenance Therapy | Sridevi Rajeeve, MD | #ASH24 YouTube video by HealthTree Foundation for Multiple Myeloma

Daratumumab vs Lenalidomide As Myeloma Maintenance Therapy | Sridevi Rajeeve, MD | #ASH24 youtu.be/oZfpQWdgiSc?...

16.12.2024 23:00 👍 2 🔁 0 💬 0 📌 0
Daratumumab + Lenalidomide Vs Lenalidomide Alone As Maintenance Therapy | Laahn Foster, MD | #ASH24
Daratumumab + Lenalidomide Vs Lenalidomide Alone As Maintenance Therapy | Laahn Foster, MD | #ASH24 YouTube video by HealthTree Foundation for Multiple Myeloma

Another Myeloma maintenance study- Auriga Study Subgroup Update - youtu.be/xKaOtop1fik?... #MMsm #ASH24 #HealthTree #myeloma

16.12.2024 22:58 👍 0 🔁 0 💬 0 📌 0
Post image

Happy to see patients as influencers at major medical meetings. It is so important to include all perspectives in the conversations. #MMsm #ASH24 #HealthTree #myeloma

15.12.2024 20:49 👍 4 🔁 0 💬 0 📌 0
Daratumumab vs Observation in High-Risk SMM (Aquila Study) | Meletios Dimopoulos, MD | #ASH24
Daratumumab vs Observation in High-Risk SMM (Aquila Study) | Meletios Dimopoulos, MD | #ASH24 YouTube video by HealthTree Foundation for Multiple Myeloma

To treat or not to treat (HR-SMM) - Listen to @thanosdimop talk about the results of the Aquila trial #MMsm #ASH24 #HealthTree #myeloma youtu.be/C7f-cTLBBfo

15.12.2024 15:29 👍 2 🔁 0 💬 0 📌 0
Iberdomide Combos Post-ASCT in Myeloma: Eliminating Residual Disease (COMMANDER) |Dr. Costa | #ASH24
Iberdomide Combos Post-ASCT in Myeloma: Eliminating Residual Disease (COMMANDER) |Dr. Costa | #ASH24 YouTube video by HealthTree Foundation for Multiple Myeloma

Reaching MRD negativity is the goal of #myeloma treatment. The CoMMander trial used Iberdomide to achieve this in Post-ASCT patients who had residual disease after 100 days. @healthtreeorg.bsky.social #MMSM #ASH24 m.youtube.com/watch?v=MiWM...

15.12.2024 02:51 👍 12 🔁 2 💬 0 📌 0
Post image

New-to-blue but feared by myeloma and well-known to the myeloma world: @drmhb.bsky.social moderating #ASH24 myeloma treatment session

09.12.2024 00:30 👍 12 🔁 2 💬 0 📌 0
Tri-specific Antibody SAR442257 in RRMM and Non- Hodgkin Lymphoma | Fredrik Schjesvold | #ASH24
Tri-specific Antibody SAR442257 in RRMM and Non- Hodgkin Lymphoma | Fredrik Schjesvold | #ASH24 YouTube video by HealthTree Foundation for Multiple Myeloma

Tri-specific Antibody #SAR442257 in RRMM and Non- Hodgkin Lymphoma
#MMsm #ASH24 #HealthTree #myeloma
youtu.be/7NzP-E9WnRo

14.12.2024 03:47 👍 4 🔁 0 💬 0 📌 0
Phase 1 Study of Antio-cel an Anti-BCMA CAR-T for RRMM | Michael Bishop | #ASH24
Phase 1 Study of Antio-cel an Anti-BCMA CAR-T for RRMM | Michael Bishop | #ASH24 YouTube video by HealthTree Foundation for Multiple Myeloma

There is a new CAR on the block and it’s performing exceptionally well. This is one of the many videos that is posted on the @HealthTree for Multiple Myeloma YouTube channel where our ASH coverage will be featured . #MMsm #ASH24 #HealthTree #myeloma

youtu.be/sx89o8X7vvU

14.12.2024 03:37 👍 3 🔁 0 💬 0 📌 0

Thanks for including a patient advocate on this important research project! #MMsm #ASH24 #HealthTree #myeloma

14.12.2024 03:22 👍 4 🔁 0 💬 0 📌 0
Post image

Myeloma / Plasma Cell Dyscrasia ~ #ASH24Top10 (or so) #mmsm #mmMRD #ASH24 - @mtmdphd - Update: 12/4/24 - cc @grpetersen1 - @bdermanmd @bhemato @DrOlaLandgren @End_myeloma @HadidiSamer @jmikhaelmd @ManniMD1 @MeeraMohanMD @MyelomaTeacher @RahulBanerjeeMD @rajshekharucms @szusmani @Taxkourel @VincentRK

05.12.2024 00:50 👍 8 🔁 2 💬 0 📌 0
Post image

Myeloma / Plasma Cell Dyscrasia ~ #ASH24Top10 (or so) #mmsm #mmMRD #ASH24 - @mtmdphd *DRAFT* Table Update: Nov 26, 2024 v2 - cc @grpetersen1 - @bdermanmd @HadidiSamer @jmikhaelmd @MyelomaTeacher @RahulBanerjeeMD @rajshekharucms @szusmani et al.

27.11.2024 04:45 👍 4 🔁 3 💬 0 📌 0
Post image

Myeloma / Plasma Cell Dyscrasia ~ #ASH24Top10 (or so) #mmsm #mmMRD #ASH24 - @mtmdphd *DRAFT* Table Update: Nov 20, 2024 - cc @grpetersen1 - @HadidiSamer @jmikhaelmd @MyelomaTeacher @RahulBanerjeeMD
@szusmani et al.

20.11.2024 18:19 👍 11 🔁 4 💬 0 📌 0
Friendship bracelets

Friendship bracelets

Who is going to #ASH24?!

And who is bringing bracelets to trade?!

17.11.2024 15:08 👍 97 🔁 7 💬 14 📌 2